Ukraine’s Darnitsa Pharmaceutical invests 3.5 million euros in R&D

Darnitsa Pharmaceutical, one of Ukraine’s largest pharmaceutical producers, invested close to 3.5 million euros in research and development in 2018, Open4Business Ukraine has reported.

“Every year we invest about 10 per cent of gross income in development and research. In 2018 the amount of such investments totaled 3.5 million euros,” Dmytro Shymkiyv, chairman of the board of directors of Darnitsa Group said during a press conference, adding that in total, Darnitsa has invested about 200 million euros in development.

Mr Shymkiv noted that the company, which brought 10 new products to the Ukrainian market last year, was planning to bring 11 new brands in 2019 and another 14 in 2020.

According to him, the company’s development strategy will focus on three key areas – cardiology, neurological drugs and pain therapy.

Darnitsa Group, which is among the top 10 pharmaceutical suppliers of Ukraine, has a product portfolio of 250 finished medicines.